

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for selecting a therapy comprising administration of a fluoropyrimidine and a platinum drug to treat therapeutic regimen for treating a cancer in a human metastatic colorectal cancer patient wherein a chemotherapeutic drug is administered to the patient, the method comprising screening a suitable cell or tissue sample isolated from said patient for the genotype at codon 118 of the ERCC1 gene, wherein the patient is selected for treatment with said therapy based on the presence of the genotype (C/C) a genomic polymorphism or genotype that is correlative to treatment outcome of the cancer.
2. (Canceled)
3. (Canceled)
4. (Currently Amended) The method of claim 2, wherein the cancer treatment therapy further comprises radiation therapy.
5. (Canceled)
6. (Canceled)
7. (Withdrawn) A method for reducing chemically induced neurotoxicity associated with cancer chemotherapy in a patient comprising administering to said subject an effective amount of a COX-2 inhibitor to a patient in need thereof.
8. (Withdrawn) The method of claim 7, wherein the chemotherapy comprises administration of oxaliplatin.

9. (Withdrawn) The method of claim 7, wherein the chemotherapy comprises administration of 5-FU.
10. (Withdrawn) A method for determining if a human patient is more likely to experience tumor recurrence after surgical removal of said tumor, comprising determining the expression level of a gene selected from the group consisting of TS, DPD, ERCC1 and VEGF, in a cell or sample isolated from normal tissue adjacent to said tumor and correlating said expression level with normal levels, wherein overexpression of said gene is predictive to identify patients at risk for tumor recurrence.
11. (Withdrawn) The method of claim 11, wherein the tumor is associated with rectal cancer.
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (New) The method of claim 1, wherein the fluoropyrimidine is 5-Fluorouracil.
17. (New) The method of claim 1, wherein the platinum drug is oxaliplatin.
18. (New) The method of claim 1, wherein the fluoropyrimidine is 5-Fluorouracil and the platinum drug is oxaliplatin.
19. (New) A method for determining whether a human metastatic colorectal cancer is likely to experience longer survival following treatment comprising the administration of a fluoropyrimidine and a platinum drug, comprising screening a cell or tissue sample isolated from said patient for the genotype at codon 118 of the ERCC1 gene, and

-5-

wherein the presence of the genotype (C/C) at codon 118 of the ERCC1 gene indicates said patient is likely to experience longer survival following treatment with said therapy.

20. (New) The method of claim 19, wherein the fluoropyrimidine is 5-Fluorouracil.
21. (New) The method of claim 19, wherein the platinum drug is oxaliplatin.
22. (New) The method of claim 19, wherein the fluoropyrimidine is 5-Fluorouracil and the platinum drug is oxaliplatin.
23. (New) The method of claim 19, wherein the therapy further comprises radiation therapy.
24. (New) A method for determining whether a human metastatic colorectal cancer patient is less likely to experience longer survival following treatment comprising the administration of a fluoropyrimidine and a platinum drug, comprising screening a cell or tissue sample isolated from said patient for the genotype at codon 118 of the ERCC1 gene, wherein the presence of the genotype (C/T) or (T/T) indicates said patient is less likely to experience longer survival following treatment with said therapy.
25. (New) The method of claim 24, wherein the fluoropyrimidine is 5-Fluorouracil.
26. (New) The method of claim 24, wherein the platinum drug is oxaliplatin.
27. (New) The method of claim 24, wherein the fluoropyrimidine is 5-Fluorouracil and the platinum drug is oxaliplatin.
28. (New) The method of claim 24, wherein the therapy further comprises radiation therapy.

29. (New) A method for treating a human metastatic colorectal cancer patient comprising administering an effective amount of a therapy comprising a fluoropyrimidine and a platinum drug to a patient selected for said therapy based on the possession of the genotype (C/C) at codon 118 of the ERCC1 gene in a cell or tissue sample isolated from said patient containing codon 118 of the ERCC1 gene.

30. (New) The method of claim 29, wherein the therapy further comprises radiation therapy.

31. (New) The method of claim 29, wherein the fluoropyrimidine is 5-Fluorouracil.

32. (New) The method of claim 29, wherein the platinum drug is oxaliplatin.

33. (New) The method of claim 29, wherein the fluoropyrimidine is 5-Fluorouracil and the platinum drug is oxaliplatin.